New drug tested for tough-to-treat blood cancers in japan
NCT ID NCT05673460
Summary
This early-stage study tested the safety and side effects of an experimental drug called nemtabrutinib in Japanese patients with various B-cell blood cancers. The trial involved 7 participants who had already tried other treatments that didn't work well for them. Researchers measured how the drug moved through the body and looked for early signs of whether it might help control these cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MATURE B-CELL NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chiba Cancer Center ( Site 0005)
Chiba, 260-8717, Japan
-
Kindai University Hospital ( Site 0006)
Sayama, Osaka, 589-8511, Japan
-
Kyushu University Hospital ( Site 0008)
Fukuoka, 812-8582, Japan
-
Nagoya University Hospital ( Site 0003)
Nagoya, Aichi-ken, 466-8560, Japan
-
National Cancer Center Hospital East ( Site 0002)
Kashiwa, Chiba, 2778577, Japan
-
Okayama University Hospital ( Site 0007)
Okayama, 700-8558, Japan
-
Yamagata University Hospital ( Site 0001)
Yamagata, 990-9585, Japan
Conditions
Explore the condition pages connected to this study.